about
Recent advances in oral vaccine development: yeast-derived β-glucan particlesCompounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusIn vitro cutaneous application of ISCOMs on human skin enhances delivery of hydrophobic model compounds through the stratum corneum.An overview of cancer immunotherapy.Structure of immune stimulating complex matrices and immune stimulating complexes in suspension determined by small-angle x-ray scattering.Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probesRecombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant.NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.Preparation and evaluation of an experimental iscom-based infectious bursal disease vaccineVaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term.A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.A comparison of pseudo-ternary diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by lipid-film hydration and dialysis.Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes
P2860
Q27001699-832D00C4-12D0-443B-AEDA-9741F67F19D0Q28084005-96745DF5-FF92-4E5B-966A-CFA57F33502CQ33513233-52F75FE4-F667-48DE-A7E0-E770E4C2B1F7Q33940388-ECDAF14B-5126-49E2-90D7-85EE0A5E3643Q35962580-EA5D53F9-7B63-40EC-AD26-A6534DCE693BQ36216866-A6745DB7-924F-41AB-903C-745B1062C72CQ36986730-F5C93BEE-EE3D-4AE0-9089-49AA265C3644Q37523971-1D401368-14E5-4F66-AB65-10DB9C61333BQ38282887-35348081-C24B-4A59-A38D-00F7FEA3D0DAQ39150340-E74F59FC-7E73-46F8-9D6D-19D3136F1200Q39945745-DFC8820D-5B0C-4CDE-95A0-2E1454BC87A5Q41034036-C2A22F9F-6834-43C9-870F-39FA421CAF8EQ42505471-06033CF0-8FD0-407C-8443-B751614C7F9CQ43211393-75E736E6-579C-4BA5-8EE2-4C4E5E3E9120Q44545688-339E04B8-4E15-45BD-B96B-990520BA8E82Q44895282-4FD600D0-1903-4EFE-9322-D7E8EAAC2C24Q46816112-EA3BE8FA-BE14-4572-BE45-0FCEC27DB27BQ59235261-0659BF75-6811-4B2E-B4E0-A4E1B859FFBE
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
ISCOMs (immunostimulating complexes): the first decade.
@en
type
label
ISCOMs (immunostimulating complexes): the first decade.
@en
prefLabel
ISCOMs (immunostimulating complexes): the first decade.
@en
P2860
P356
P1476
ISCOMs (immunostimulating complexes): the first decade.
@en
P2093
P2860
P2888
P356
10.1038/ICB.1996.2
P577
1996-02-01T00:00:00Z
P5875
P6179
1030452400